Difference between revisions of "Secondary amyloidosis diagnostic study of choice"

Jump to: navigation, search
(Diagnostic Criteria)
 
Line 7: Line 7:
 
==Diagnostic Study of Choice==
 
==Diagnostic Study of Choice==
 
* Since AA amyloidosis is a [[condition]] that occurred due to another [[illness]], the [[diagnostic]] study of choice varies according to the primary [[disorder]].<ref name="LachmannGoodman2007">{{cite journal|last1=Lachmann|first1=Helen J.|last2=Goodman|first2=Hugh J.B.|last3=Gilbertson|first3=Janet A.|last4=Gallimore|first4=J. Ruth|last5=Sabin|first5=Caroline A.|last6=Gillmore|first6=Julian D.|last7=Hawkins|first7=Philip N.|title=Natural History and Outcome in Systemic AA Amyloidosis|journal=New England Journal of Medicine|volume=356|issue=23|year=2007|pages=2361–2371|issn=0028-4793|doi=10.1056/NEJMoa070265}}</ref>
 
* Since AA amyloidosis is a [[condition]] that occurred due to another [[illness]], the [[diagnostic]] study of choice varies according to the primary [[disorder]].<ref name="LachmannGoodman2007">{{cite journal|last1=Lachmann|first1=Helen J.|last2=Goodman|first2=Hugh J.B.|last3=Gilbertson|first3=Janet A.|last4=Gallimore|first4=J. Ruth|last5=Sabin|first5=Caroline A.|last6=Gillmore|first6=Julian D.|last7=Hawkins|first7=Philip N.|title=Natural History and Outcome in Systemic AA Amyloidosis|journal=New England Journal of Medicine|volume=356|issue=23|year=2007|pages=2361–2371|issn=0028-4793|doi=10.1056/NEJMoa070265}}</ref>
 
 
* However, the amyloidosis itself should be confirmed through [[histologic]] examination of the affected organs.  
 
* However, the amyloidosis itself should be confirmed through [[histologic]] examination of the affected organs.  
 
* A [[Tissue (biology)|tissue]] [[biopsy]] of the affected organ is the [[Gold standard (test)|gold standard test]] for amyloidosis. Particular stains can determine the subtype of amyloidosis.
 
* A [[Tissue (biology)|tissue]] [[biopsy]] of the affected organ is the [[Gold standard (test)|gold standard test]] for amyloidosis. Particular stains can determine the subtype of amyloidosis.

Latest revision as of 22:09, 10 November 2019

Secondary amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Secondary amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Secondary amyloidosis diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Secondary amyloidosis diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Secondary amyloidosis diagnostic study of choice

CDC on Secondary amyloidosis diagnostic study of choice

Secondary amyloidosis diagnostic study of choice in the news

Blogs on Secondary amyloidosis diagnostic study of choice

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Secondary amyloidosis diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]Shyam Patel [3]

Overview

The diagnostic study of choice in amyloidosis is tissue biopsy of the affected organ. Urinary protein measurement followed by renal biopsy is the gold standard of the diagnosis.

Diagnostic Study of Choice

  • Since AA amyloidosis is a condition that occurred due to another illness, the diagnostic study of choice varies according to the primary disorder.[1]
  • However, the amyloidosis itself should be confirmed through histologic examination of the affected organs.
  • A tissue biopsy of the affected organ is the gold standard test for amyloidosis. Particular stains can determine the subtype of amyloidosis.
  • Kidney is affected to a greater extent compared to other organs. The 24-hour urine collection with the assessment of urinary protein may be useful and in the case of renal involvement, a kidney biopsy is required.
  • Staining the tissue sample with antibodies that are specific for AA amyloidosis will confirm the final diagnosis.
  • Organ-specific labs: If a particular organ is affected, laboratory measurements that are specific to that organ can be measured. For example, if there is liver involvement, liver function tests (such as AST, ALT, total bilirubin, and alkaline phosphatase) should be measured.[2]

Diagnostic Criteria

  • Following diagnostic criteria has been used for AL amyloidosis. However, it may be applicable for AA amyloidosis as well.[3]
The table below adopted from Clinical Epidemiology Journal
Diagnostic Criteria
Organ Criteria
Kidney
  • > 0.5 g/day protein loss, predominantly albumin in 24-hour urine collection
Heart
Liver
Nerve
  • Symmetric lower extremity sensorimotor peripheral neuropathy on physical examination
  • Presence of orthostatic hypotension due to autonomic nerve involvement
  • Intestinal dysmotility (gastric emptying disorder, pseudo-obstruction, voiding dysfunction)
Gastrointestinal tract
  • Histologic examination consistent with amyloidosis histology
Lung
  • Diffuse bilateral interstitial pattern on the imaging studies
  • Histologic examination consistent with the diagnosis of amyloidosis
Skin and soft tissue

References

  1. Lachmann, Helen J.; Goodman, Hugh J.B.; Gilbertson, Janet A.; Gallimore, J. Ruth; Sabin, Caroline A.; Gillmore, Julian D.; Hawkins, Philip N. (2007). "Natural History and Outcome in Systemic AA Amyloidosis". New England Journal of Medicine. 356 (23): 2361–2371. doi:10.1056/NEJMoa070265. ISSN 0028-4793.
  2. Gertz, Morie A.; Comenzo, Ray; Falk, Rodney H.; Fermand, Jean Paul; Hazenberg, Bouke P.; Hawkins, Philip N.; Merlini, Giampaolo; Moreau, Philippe; Ronco, Pierre; Sanchorawala, Vaishali; Sezer, Orhan; Solomon, Alan; Grateau, Giles (2005). "Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis". American Journal of Hematology. 79 (4): 319–328. doi:10.1002/ajh.20381. ISSN 0361-8609.
  3. Real de Asua, Diego; Galvan, Jose Maria; Filigghedu, Maria Teresa; Trujillo, Davinia; Costa, Ramon; Cadinanos, Julen (2014). "Systemic AA amyloidosis: epidemiology, diagnosis, and management". Clinical Epidemiology: 369. doi:10.2147/CLEP.S39981. ISSN 1179-1349.



Linked-in.jpg